CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
实体瘤的 CAR-T 细胞治疗
英文原题：Chimeric Antigen Receptor T Cell Therapy For Solid Tumors.
查看英文原题
Chimeric Antigen Receptor T Cell Therapy For Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法已经彻底改变了淋巴系统恶性肿瘤的治疗。然而，它仍处于早期阶段，在实体瘤中面临许多障碍。实体瘤中的治疗挑战导致肿瘤靶点多样化，并推动新的创新以提高临床疗效。本综述展示了早期临床工作，并阐明了最显著的成就、缺陷以及为使CAR-T 疗法全速前进所采用的策略。
展开英文摘要原文
Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the management of lymphoid malignancies.
However, it is still in its early phase and is facing many obstacles in solid tumors. Therapeutic challenges in solid tumor lead to tumor target diversification and drive new innovations for the improvement of clinical efficacy. This review showcases early clinical works and sheds light on the most notable successes, drawbacks, and strategies employed to allow CAR T therapy to go full speed ahead.
论文信息
- 作者
- Hsu J、Yang Y、Gergis M、Bi X、Yi D、Gergis U
- 第一作者单位
- Weill Cornell Medicine, United States.United States
- 通讯作者单位
- Thomas Jefferson University Sidney Kimmel Medical College, United States.United States
- 文献类型
- 综述
- 期刊
- Hematology/oncology and stem cell therapy2022 Dec 15
- 原文标识
- PubMed 36537910 · DOI 10.56875/2589-0646.1028